The Application of Structural Retinal Biomarkers to Evaluate the Effect of Intravitreal Ranibizumab and Dexamethasone Intravitreal Implant on Treatment of Diabetic Macular Edema

• DOI: 10.3390/diagnostics10060413
• Publication Date: 2020-06-17T17:11:32Z
• Authors: Ida Ceravolo; Giovanni William ...; Angela Alibrandi; Ahsan Bhatti; Luigi Trombetta; Robert Rejdak; Mario Damiano Toro; Costantino John T...
• Keywords: Diabetic macular edema

The aim of this study was to compare the therapeutic effect intravitreal treatment with ranibizumab and dexamethasone using specific swept-source optical coherence tomography retinal biomarkers in patients diabetic macular edema (DME).156 treatment-naïve DME were divided two groups: 75 received 3 monthly injections 0.5 mg (Lucentis®) (Group 1) 81 an implant 0.7 (Ozurdex®) 2). Patients evaluated at baseline (V1), three months post-treatment Group 1, 2 (V2). Best-corrected visual acuity (BCVA) swept source-OCT recorded each interval. Changes between V1 V2 analyzed Wilcoxon test differences groups assessed Mann-Whitney test. Multiple regression analysis performed evaluate possible OCT biomarker (CRT, ICR, CT, SND, HRS) as predictive factors for final improvement.In both groups, BCVA improved (p-value < 0.0001), a significant reduction central thickness, intra-retinal cysts, red dots, hyper-reflective spots (HRS), serous detachment neuro-epithelium (SDN) observed. A superiority over reducing SDN height = 0.03) HRS 0.01) documented.Ranibizumab are effective DME, demonstrated by functional improvement morphological change. associated represents inflammatory pattern which appears be more effective.